New Biomarkers of Neurological Outcome in Patients With Sudden Cardiac Death: Role of Circulating Microparticles
Overview
- Phase
- Not Applicable
- Intervention
- Not specified
- Conditions
- Cardiac Sudden Death
- Sponsor
- Fundació Institut de Recerca de l'Hospital de la Santa Creu i Sant Pau
- Enrollment
- 84
- Locations
- 1
- Primary Endpoint
- Change in Glasgow-Pittsburgh Cerebral Performance Categories Scale for neurological outcome.
- Last Updated
- 6 years ago
Overview
Brief Summary
The aim of the project is to establish the value of circulating microparticles as a new biomarker for neurological prognosis of patients recovered from sudden cardiac death who remain comatose.
Detailed Description
This is a pilot study. Analytical, observational, longitudinal, retrospective and prospective, non-randomized. Patients recovered from sudden cardiac death of ischemic cause and remain comatose will be included in the protocol if they fit the pre-specified inclusion criteria. Biological samples will be collected (at admission, at 24 and 72 hours) and stored in the Biobank of Hospital de la Santa Creu i Sant Pau for further analysis. In addition demographic, clinical and analytical variables will be collected. At the end of the recruitment period, we will analyse the concentrations of circulating microparticles according to ICCC-IIBSantPau methodology in the samples obtained. The primary outcome variable will be the neurological status at Coronary Care Unit discharge and at 6 months. The objective of the study will evaluate the relationship between the neurological status and the blood concentrations of circulating microparticles.
Investigators
Eligibility Criteria
Inclusion Criteria
- •Over 18 years old.
- •Patients recovered from a sudden cardiac death (in-hospital and out-of-hospital) with return of spontaneous circulation (ROSC) (defined as systolic blood pressure \> 60 mmHg or palpable pulse for \> 5 minutes) who remain unconsciousness (defined as a score on the Glasgow Coma Scale \<8 ) for \> 5-10 minutes after ROSC.
- •Treated with hypothermia as recommended by the European guidelines for resuscitation ( 2010)..
Exclusion Criteria
- •Non-cardiac sudden death.
- •Active oncologic pathology .
- •Traumatic or spontaneous intra-cranial haemorrhage.
- •Inability to obtain required blood samples or refusal of the informed consent necessary for it.
Outcomes
Primary Outcomes
Change in Glasgow-Pittsburgh Cerebral Performance Categories Scale for neurological outcome.
Time Frame: Change from Glasgow-Pittsburgh Cerebral Performance Categories Scale at 6 months
1. Good cerebral performance: conscious, alert, able to work, might have mild neurologic or psychologic deficit. 2. Moderate cerebral disability: conscious, sufficient cerebral function for independent activities of daily life. Able to work in sheltered environment. 3. Severe cerebral disability: conscious, dependent on others for daily support because of impaired brain function. Ranges from ambulatory state to severe dementia or paralysis. 4. Coma or vegetative state: any degree of coma without the presence of all brain death criteria. Unawareness, even if appears awake (vegetative state) without interaction with environment; may have spontaneous eye opening and sleep/awake cycles. Cerebral unresponsiveness. 5. Brain death: apnea, areflexia, EEG silence, etc.
Secondary Outcomes
- Cardiovascular mortality(6 months)